Table 1.
Baseline characteristics
| HIV negative |
HIV positive |
|||
|---|---|---|---|---|
| Control | Virologic suppression | Virologic nonsuppression | All HIV-positive participants | |
| n | 26 | 22 | 9 | 31 |
| Males, % | 89 | 91 | 100 | 94 |
| Age, years | 39.0 (32.5, 40.6) | 41.3 (35.7, 49.4) | 37.9 (35.4, 44.8) | 41.2 (35.6, 47.3) |
| Ethnicity, % White | 58 | 50 | 56 | 52 |
| Duration of HIV infection, years | – | 7.0 | 10.5 | |
| Duration of ART use, years | – | 4.2 | 6.5 | |
| Body mass index, kg/m2 | 24.1 (21.7, 28.1) | 24.7 (22.8, 26.0) | 24.8 (22.0, 27.4) | 24.7 (22.8, 26.1) |
| Heart rate, beats/min | 68.0 (60.5, 72.0) | 68.0 (60.0, 73.0) | 68.0 (64.0, 80.0) | 68.0 (64.0, 76.0) |
| Systolic blood pressure, mm Hg | 110.0 (103.5, 115.0) | 106.5 (99.8, 116.8) | 119 (113.0, 123.5)** | 110.0 (103.0, 120.0) |
| Diastolic blood pressure, mm Hg | 73.5 (67.5, 78.3) | 72.5 (69.6, 81.5) | 74.0 (69.5, 79.5) | 73.0 (69.0, 80.0) |
| Nadir CD4, cells/mm3 | – | 313.5 (248.0, 600.8) | 252.0 (37.5, 346.0)** | 305 (183, 531) |
| CD4, cells/mm3 | – | 532.5 (369.5, 707.5) | 252.0 (79.0, 346.0)** | 426 (252, 629) |
| HIV RNA PCR, copies/mL | – | – | 400 (113, 32750)** | 0 (0, 111) |
| Fasting glucose, mg/dL | 86.5 (80.8, 92.0) | 85.0 (77.5, 91.3) | 89.0 (77.0, 91.0) | 86.0 (78.0, 91.0) |
| Insulin, uIU/mL | 4.3 (2.8, 7.7) | 6.0 (4.0, 8.1) | 5.0 (3.5, 11.6) | 6.0 (4.0, 7.5) |
| Homeostasis Model Assessment (HOMA-IR) | 0.9 (0.6, 1.8) | 1.2 (0.9, 1.7) | 1.1 (0.6, 2.6) | 1.2 (0.9, 1.7) |
| sE-Selectin, ng/mL | 23.1 (19.5, 28.8) | 21.6 (16.6, 27.5) | 22.5 (17.3, 31.1) | 22.1 (17.0, 28.7) |
| sVCAM-1, ng/mL | 1115 (956, 1317) | 1240 (1000, 1450) | 1220 (1065, 1385) | 1230 (1023, 1403) |
| sICAM-1, ng/mL | 202.0 (166.0, 246.5) | 212.0 (188.0, 279.0) | 272.0 (207.5, 310.5)* | 229.0 (188.8, 292.0)* |
| adiponectin, ng/mL | 10150 (7463, 14350) | 7800 (4660, 16300) | 9880 (6410, 13050) | 7910 (6033, 13225) |
| tPAI-1, ng/mL | 14.3 (6.7, 20.5) | 12.3 (6.5, 26.9) | 19.5 (8.4, 26.8) | 13.9 (7.6, 25.7) |
Note: Continuous variables are displayed as medians (Q1, Q3).
*
P < .05 compared to HIV seronegative controls.
**
P < .05 compared to HIV-infected virologic suppression group.